Edition:
India

Quidel Corp (QDEL.OQ)

QDEL.OQ on NASDAQ Stock Exchange Global Select Market

69.59USD
20 Jul 2018
Change (% chg)

$-0.22 (-0.32%)
Prev Close
$69.81
Open
$69.82
Day's High
$70.10
Day's Low
$69.26
Volume
63,679
Avg. Vol
114,318
52-wk High
$71.21
52-wk Low
$31.08

Chart for

About

Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: immunoassays, molecular assays, virology and specialty products. The Company sells its products directly to end users and distributors, in... (more)

Overall

Beta: 1.22
Market Cap(Mil.): $1,436.60
Shares Outstanding(Mil.): 33.44
Dividend: --
Yield (%): --

Financials

BRIEF-Quidel Reports Q1 Non-GAAP Earnings Per Share $1.29

* Q1 REVENUE $169.1 MILLION VERSUS I/B/E/S VIEW $150.9 MILLION

09 May 2018

BRIEF-Quidel Corp Says Increased Size Of Board To Eight Members - SEC Filing

* QUIDEL CORP SAYS INCREASED SIZE OF COMPANY'S BOARD OF DIRECTORS TO EIGHT MEMBERS - SEC FILING Source text (https://bit.ly/2q4dLBG) Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

05 Apr 2018

BRIEF-Quidel Receives FDA Clearance For Its Instrument

* QUIDEL RECEIVES FDA CLEARANCE FOR ITS POINT-OF-CARE SOFIA® LYME FLUORESCENT IMMUNOASSAY FOR USE WITH SOFIA® 2 INSTRUMENT Source text for Eikon: Further company coverage:

06 Mar 2018

BRIEF-Quidel Q4 Non-Gaap Earnings Per Share $0.56

* QUIDEL REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

22 Feb 2018

BRIEF-Quidel Receives 510(K) Clearance For Quickvue Influenza A+B Test

* QUIDEL RECEIVES 510(K) CLEARANCE FOR QUICKVUE INFLUENZA A+B TEST, ASSAY MEETS FDA'S CLASS II RIDT REQUIREMENTS

14 Feb 2018

Competitors

Earnings vs. Estimates